Table 1.
Characteristics of the study population.
| Non-HT Patients (A-TPO Negative, n = 100) |
HT Patients (A-TPO Positive, n = 100) |
p Value | |
|---|---|---|---|
| Female, n | 76 (76.0%) | 77 (77.0%) | 1.000 |
| Age, y | 55.0 (46.0–62.5) | 56.0 (47.5–63.5) | 0.689 |
| A-TPO, U/mL | 28.0 (28.0–33.4) | 1300 (245–1300) | <0.001 |
| A-Tg, U/mL | 1.3 (1.3–1.3) | 8.3 (2.2–48.1) | <0.001 |
| A-Tg > 4.5 U/mL | 0 (0.0%) | 60 (60.6%) * | <0.001 |
| TSH, μIU/mL | 1.705 (1.120–2.660) | 2.215 (1.135–4.155) | 0.025 |
| ASCA, U/mL | 2.1 (1.2–3.9) | 2.2 (1.0–4.1) | 0.790 |
| ASCG, U/mL | 1.3 (0.7–2.9) | 1.7 (0.6–4.4) | 0.302 |
| ACCP, U/mL | 1.1 (0.9–1.3) | 1.0 (0.8–1.2) | 0.254 |
| tTG IgA, U/mL | 0.5 (0.3–0.8) | 0.5 (0.3–0.7) | 0.785 |
| tTG IgG, U/mL | 0.8 (0.6–0.9) | 0.7 (0.6–0.8) | 0.109 |
| APCA > 1:80, n | 4 (4.1%) * | 16 (16.3%) * | 0.008 |
| AMA > 1:80, n | 3 (3.0%) * | 0 (0.0%) | n.a. |
| GAD > 10 U/mL, n | 3 (3.0%) | 2 (2.0%) | n.a. |
| IA2 > 10 U/mL, n | 1 (1.0%) | 3 (3.0%) | n.a. |
| ZNT8 > 15 U/mL, n | 2 (2.0%) | 0 (0.0%) | n.a. |
| ANCA > 1:20, n | 10 (10.2%) | 27 (27.3%) * | 0.003 |
| ANA > 1:80, n | 44 (44.9%) * | 67 (68.4%) * | 0.001 |
| ANA > 1:320, n | 18 (18.2%) * | 22 (22.5%) * | 0.596 |
| Fluorescence ANA pattern: | 0.322 ** | ||
| - Homogeneous | 5 (11.6%) | 4 (6.0%) | |
| - Speckled | 28 (65.1%) | 37 (55.2%) | |
| - Nucleolar | 6 (14.0%) | 14 (20.9%) | |
| - Mixed/Other | 4 (9.3%) | 12 (17.9%) | |
| Screen ratio | 0.2 (0.1–0.3) | 0.1 (0.1–0.2) | 0.259 |
| ADA > 1:10, n | 0 (0.0%) | 3 (3.0%) | n.a. |
* valid percentage, calculated by excluding missing individual patient data from the analysis; ** calculated using the Chi-squared test. A-TPO, anti-thyroperoxidase antibodies; A-Tg, anti-thyroglobuline antibodies; TSH, thyrotropin stimulating hormone; ASCA, anti-saccharomyces cerevisiae antibodies IgA; ASCG, anti-saccharomyces cerevisiae antibodies IgG; ACCP, anti-cyclic citrullinated peptides antibodies; tTG IgA, anti-transglutaminase antibodies IgA; tTG IgG, anti-transglutaminase antibodies IgG; APCA, anti-parietal cells antibodies; AMA, anti-mitochondrial antibodies; GAD: glutamic acid decarboxylase; IA2, anti-tyrosin phosphatase A2 antibodies; ZnT8, anti-zinc transporters 8 antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; ANA, antinuclear antibodies; ADA, anti-adrenal cortex antibodies. Screen Ratio: ratio is automatically calculated by the instrument by comparing the signal of the test sample with that of the calibrators, specifically for U1RNP (RNP70, A, C), SS-A/Ro (60 kDa, 52 kDa), SS-B/La, Centromere B, Scl-70, Jo-1, Fibrillarin, RNA Pol III, Rib-P, PM-Scl, PCNA, Mi-2, Sm and DNA. Bold values denote statistical significance at the p < 0.05 level. n.a.: not applicable due to insufficient count numbers.